| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | PP5; REF1; TFPI-2 |
| WB Predicted band size | 27 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human TFPI2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TFPI2抗体的3篇文献示例(注：文献信息为示例性概括，具体内容需参考真实论文)：
1. **文献名称**: *"TFPI2 as a novel diagnostic biomarker in ovarian cancer: Development of a monoclonal antibody-based ELISA assay"*
**作者**: Smith A, et al.
**摘要**: 本研究开发了一种针对TFPI2蛋白的特异性单克隆抗体，并基于此建立了高灵敏度的ELISA检测方法，用于卵巢癌患者血清中TFPI2的定量分析。结果显示，TFPI2在卵巢癌组织中高表达，且血清TFPI2水平与肿瘤分期相关，提示其作为诊断标志物的潜力。
2. **文献名称**: *"Epigenetic silencing of TFPI2 in colorectal cancer: Role of antibody-based detection in clinical samples"*
**作者**: Chen L, et al.
**摘要**: 研究探讨了结直肠癌中TFPI2基因因启动子甲基化导致的表达沉默，并通过免疫组化(使用TFPI2特异性抗体)验证了其在癌组织中的表达缺失。结果表明，TFPI2抗体可作为评估结直肠癌表观遗传调控及预后的工具。
3. **文献名称**: *"Targeting TFPI2 in hepatocellular carcinoma: A therapeutic antibody approach"*
**作者**: Wang Y, et al.
**摘要**: 研究设计了一种靶向TFPI2的人源化抗体，并在肝癌细胞系和小鼠模型中验证其抗肿瘤效果。该抗体通过阻断TFPI2与肿瘤微环境中的相互作用，抑制了肿瘤血管生成和转移，为肝癌治疗提供了新策略。
4. **文献名称**: *"TFPI2 autoantibodies as a potential biomarker for early pancreatic cancer detection"*
**作者**: Gupta R, et al.
**摘要**: 通过蛋白质芯片技术筛选发现，TFPI2自身抗体在胰腺癌患者血清中显著升高。研究利用TFPI2重组蛋白和抗体进行验证，表明其可作为胰腺癌早期筛查的非侵入性生物标志物。
**提示**：以上为模拟文献，建议通过PubMed、Google Scholar等平台检索真实论文(关键词：TFPI2 antibody, diagnostic/therapeutic application)。
Tissue Factor Pathway Inhibitor 2 (TFPI2), a member of the Kunitz-type serine protease inhibitor family, plays a critical role in regulating coagulation and extracellular matrix (ECM) remodeling. Primarily secreted by endothelial cells and smooth muscle cells, TFPI2 inhibits tissue factor (TF)-dependent coagulation by targeting factor Xa and the TF-factor VIIa complex. Beyond hemostasis, it modulates ECM degradation by suppressing plasmin-mediated activation of matrix metalloproteinases (MMPs), influencing tissue repair, angiogenesis, and tumor metastasis.
TFPI2 is epigenetically silenced in various cancers (e.g., colorectal, pancreatic, and hepatocellular carcinomas) due to promoter hypermethylation, correlating with tumor progression and poor prognosis. Its downregulation enhances invasiveness by promoting ECM breakdown, making it a potential biomarker for cancer detection and therapeutic targeting.
Antibodies against TFPI2 are valuable tools in research and diagnostics. They enable quantification of TFPI2 expression in tissues or serum, aiding in cancer biomarker studies. Additionally, these antibodies help elucidate TFPI2’s functional roles in thrombosis, atherosclerosis, and pregnancy disorders like preeclampsia. Recent efforts explore therapeutic applications, such as antibody-based strategies to restore TFPI2 activity in cancers or block its interactions in pathological coagulation. However, clinical translation requires further validation of its tissue-specific mechanisms and disease associations.
×
